(NYSE: BIO) Bio Rad Laboratories's forecast annual revenue growth rate of 2.31% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 6.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.56%.
Bio Rad Laboratories's revenue in 2026 is $2,589,300,000.On average, 5 Wall Street analysts forecast BIO's revenue for 2026 to be $69,893,589,450, with the lowest BIO revenue forecast at $67,674,320,925, and the highest BIO revenue forecast at $72,834,788,700. On average, 5 Wall Street analysts forecast BIO's revenue for 2027 to be $72,112,857,975, with the lowest BIO revenue forecast at $69,973,803,975, and the highest BIO revenue forecast at $75,000,580,875.
In 2028, BIO is forecast to generate $74,091,482,925 in revenue, with the lowest revenue forecast at $71,872,214,400 and the highest revenue forecast at $77,059,420,350.